Lightbits Labs Closes Q1-2025 with Record-Breaking Growth
15.4.2025 15:01:00 CEST | Business Wire | Press Release
Lightbits Labs (Lightbits®), the inventor of the NVMe® over TCP protocol offering next-gen software-defined storage for modern workloads, today announced record-breaking growth for Q1’25. This milestone reflects strong global demand for infrastructure modernization that models Cloud Operations enabled by high-performance block storage offering flexibility, reliability, and cost-efficiency at scale.
The breakout quarter for Lightbits, marked by a 4.8X increase in software sales and a 2.9X increase in average deal size, is fueled by a surge in new customers and strong customer loyalty, as evidenced by an impressive 2X YoY license increase. New account growth was particularly strong among financial services, service providers, and e-commerce organizations who require high-performance, low-latency at massive scale.
A strong standout use case for Lightbits was among AI Cloud service providers. Crusoe expanded its use of Lightbits to power high-performance, multi-petabyte-scale AI cloud services. Elastx implemented Lightbits to support secure, scalable, and sustainable OpenStack, Kubernetes, and AI cloud services. And cloud company Nebul uses Lightbits to underpin its high-performance, cost-efficient data platform for enterprise AI deployments.
"The quarter close marked significant progress financially and strategically,” said Eran Kirzner, CEO and co-founder of Lightbits Labs. “Our growth is a direct result of the trust and value customers place in Lightbits’ solutions, delivering unmatched performance and efficiency for modern applications in containerized and virtualized environments at scale. We now service Fortune 500 financial institutions, as well as some of the world’s largest e-Commerce platforms and AI cloud companies.”
Lightbits offers best-in-class software-defined storage that redefines performance and efficiency for open source environments like Kubernetes, KVM, OpenShift, and OpenStack, delivering the industry’s best price/performance for AI/ML, analytics, and transactional workloads at scale. The storage software scales to hundreds of petabytes and delivers performance of up to 75 million IOPS and consistent sub-millisecond tail latency under a heavy load. The unique NVMe over TCP architecture utilizes resources more efficiently with less proprietary hardware, simplifying storage management and requiring 5X less hardware compared to Ceph Storage, which reduces energy consumption and satisfies sustainability strategies. To support mixed workload environments, a single Lightbits cluster provides multi-tenancy with Quality of Service capabilities to prevent resource hogging.
“Legacy storage infrastructure can and will impact application performance of data-driven environments. Thus, storage is fundamental and must be the first consideration of any modernization effort,” said Matt Kimball, Vice President & Principal Analyst at Moor Insights & Strategy. “As more organizations shift to AI and real-time data workloads, the importance of flexible, disaggregated storage solutions becomes critical. Scale matters, and performant scale is even more important. Companies like Lightbits Labs deliver performance, scale, and cost savings realized by some of the largest organizations.”
Lightbits Labs' success is further amplified by its growing global partner network, highlighted by several announcements last year:
- Lightbits Labs joined the Mirantis Partner Program, providing scalable and resilient high-performance storage for Kubernetes
- Lightbits Certified on Oracle Cloud Infrastructure
“We're seeing a consistent pattern of engagement with customers finding that other software-defined storage can only accommodate low and middle-tier workloads. They adopt Lightbits for tier 1 workloads, and then we move downstream to their utility tier, as well. And customers seeking VMware alternatives like Lightbits for its seamless integrations with OpenShift and Kubernetes to enable their infrastructure modernization,” added Rex Manseau, Chief Revenue Officer of Lightbits Labs. “The unmatched capabilities of Lightbits, combined with the compatibility with common orchestration environments, make it an ideal choice for organizations and service providers who are supporting diverse performance-sensitive workloads at scale to capitalize on rapidly expanding business opportunities.”
Recently, the company’s solutions and commitment to excellence were given industry recognition through many prestigious awards, including:
- CRN’s Storage 100
- CRN's 50 Coolest Software-Defined Storage Vendors
- Data Breakthrough Award
- SDC and Cloud Award
Lightbits also received analyst recognition from GigaOM, positioned as a Fast-Moving Leader for Primary Storage in their 2024 Primary Storage Report, further cementing its reputation in the market.
Looking ahead, Lightbits Labs is poised to expand its global install base, prioritizing key markets across the Americas and Europe, and other high-growth regions. With more new products and partnership announcements in the pipeline for later this year, the company continues to innovate and expand its footprint in the storage market and intensify its focus on delivering cutting-edge solutions for broader workload coverage.
In 2025, you can connect with Lightbits software-defined storage experts at these industry events: The Red Hat Summit, StackConf, and KubeCon.
Visit our website to learn more about why leading organizations choose Lightbits software-defined storage or book a product demonstration today.
About Lightbits Labs
Lightbits Labs® (Lightbits) invented the NVMe over TCP protocol and offers best-in-class software-defined block storage that enables data center infrastructure modernization for organizations building a private or public cloud. Built from the ground up for low consistent latency, scalability, resiliency, and cost-efficiency, Lightbits software delivers the best price/performance for real-time analytics, transactional, and AI/ML workloads. Lightbits Labs is backed by enterprise technology leaders [Cisco Investments, Dell Technologies Capital, Intel Capital, Lenovo, and Micron] and is on a mission to deliver the fastest and most cost-efficient data storage for performance-sensitive workloads at scale.
To learn more about Lightbits Labs, visit https://www.lightbitslabs.com/ and follow Lightbits Labs on Linkedin, X, Facebook, Instagram, and YouTube.
Lightbits and Lightbits Labs are registered trademarks of Lightbits Labs, Ltd.
All trademarks and copyrights are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415197129/en/
Contacts
Lightbits PR Contact:
Carol Platz
pr@lightbitslabs.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom